Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Nuscale Power Corporation — how do they compare? Definium Therapeutics Inc. Common Shares trades at $35.09 (market cap $4.59B), while Nuscale Power Corporation trades at $7.21 (market cap $3.00B). The key difference: Definium Therapeutics Inc. Common Shares is the larger of the two by market cap, and Definium Therapeutics Inc. Common Shares is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Nuscale Power Corporation for 29 Days on average.
| DFTX | SMR | |
|---|---|---|
Market Cap | $4.59B | $3.00B |
Volume | 2,103,937 | 43,143,109 |
Sector | Health | Industrials |
52-Week High | $48.45 | $53.43 |
52-Week Low | $10.68 | $7.32 |
Typical Hold Time | 0 Days | 29 Days |
Enterprise Value | $3.55B | $1.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NuScale Power (SMR) trades at $7.67, down 4.42% today, reflecting ongoing investor concerns about the company's financial performance. The stock shows bearish technical signals with negative moving averages and oscillators, while fundamentally the company faces significant challenges with a net income margin of -3,888.7% and negative cash flow from operations of $459.61 million in 2025. Recent news highlights both the nuclear industry's growth potential and specific challenges facing NuScale, including ongoing legal investigations.
Despite analyst consensus pointing to potential upside with a $11.25 price target, SMR faces substantial execution risks as it burns cash while pursuing commercialization. The company's ability to secure additional financing and achieve revenue growth will be critical for survival, making this a high-risk investment suitable only for investors comfortable with speculative nuclear technology plays.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
